Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.61 |
| ▸ | CHUK | O15111 | 2/20 | 0.61 |
| ▸ | ABL1 | P00519 | 6/20 | 0.57 |
| ▸ | BCR | P11274 | 6/20 | 0.57 |
| ▸ | PRKCA | P17252 | 5/20 | 0.57 |
| ▸ | SRC | P12931 | 3/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893321 | 0.91 | ABL1 (0.69) | IKBKBCHUKABL1BCRPRKCA | |
| SCHEMBL6667467 | 0.90 | ABL1 (0.60) | IKBKBCHUKABL1BCRPRKCA | |
| SCHEMBL4903401 | 0.89 | IKBKB (0.67) | IKBKBCHUKPLK1ALDH1A1 | |
| SCHEMBL6041185 | 0.87 | CYP19A1 (0.58) | IKBKBCHUKABL1BCRPRKCA | |
| SCHEMBL4905681 | 0.85 | ABL1 (0.57) | IKBKBCHUKABL1BCRPRKCA | |
| SCHEMBL4904242 | 0.84 | KIT (0.56) | IKBKBCHUKABL1BCRPRKCA | |
| SCHEMBL4899549 | 0.81 | IKBKB (0.61) | IKBKBCHUKABL1BCRPRKCA | |
| SCHEMBL4899574 | 0.80 | ABL1 (0.76) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL4897551 | 0.80 | ABL1 (0.69) | IKBKBABL1BCRPRKCASRC | |
| SCHEMBL5777773 | 0.79 | ABL1 (0.57) | ABL1BCRPRKCASRCPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | IKBKB 717/4885CHUK 293/4885ABL1 901/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | IKBKB 651/4885CHUK 296/4885ABL1 904/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | IKBKB 875/4885CHUK 597/4885ABL1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.